logo
The U.S. Army's $170,000 Attack Drone Competes With $500 FPVs

The U.S. Army's $170,000 Attack Drone Competes With $500 FPVs

Forbes10-07-2025
The SwitchBlade 600 is the Army's choice for its LASSO project
New budget documents show that the U.S. Army is making a little headway in its efforts to catch up with Ukraine and Russia acquiring small attack drones like the ubiquitous FPVs. But they also show there is still a very long way to go, and rather than abundant low-cost systems, the Army will be fielding a few expensive systems for the immediate future.
Low Altitude Stalking And Strike
Two years ago, back in July 2023, the U.S. Army announced a new Low Altitude Stalking and Strike Ordnance (LASSO) program. The new weapon was on an 'an urgent capability acquisition pathway to rapidly deliver this capability to the Infantry Brigade Combat Team (IBCT).'
The project was clearly inspired by Ukraine, where small FPV quadcopters were taking out Russian armor at long range, and would give the Army similar capability
'LASSO is a man-portable, tube launched, lethal payload munition, unmanned aerial system. It includes electrical optical /infrared sensor, precision flight control, and the ability to fly, track and engage non-line-of-sight targets and armored vehicles with precision lethal fires. LASSO currently consists of three modules: the launch tube, unmanned aerial system, and fire control station.'
A U.S. marine with a tube-launched attack drone (note gas supply for the launcher)
The big difference here is that LASSO would have an infrared sensor or thermal imager, These are still rare on FPVs because they typically add $200-$500 to the cost, so daytime FPVs generally lack them. And while in Ukraine FPVs are carried in a backpack and launched from a stand, the U.S. Army wanted a tube-launched version. This would be fired out by compressed air or other gas, then unfold its wings, making for a quicker and easier launch but at the cost of some cost and complexity.
The LASSO requirement is for a 20-kilometer range and the ability to destroy armored vehicles including tanks, doing the same job as FPVs,
There are a wide variety of FPVs in use in Ukraine, varying in size, payload and extras. Typically, they cost around $500. Ukrainian drone fundraiser Serhii Sternenko – who has supplied a staggering 200,000 FPVs to the military, and targeted by an assassin as a result -- – quotes $300 for a small 7-inch FPV and $460 for a 10-inch, On the other side, Russian maker Frobotics offers an entry-level model for $315 and heavy lift (20-pound warhead) for $756.
Ukraine is building vast numbers of FPV attack drones
These are made in vast numbers. Ukraine recently announced it had increased drone production to 200,000 per month or about 6,000 per day.
In December 2023 AeroVironment announced that the Army had selected their SwitchBlade 600 for the LASSO requirement. The Switchblade 600, launched in 2020, is the big brother to the SwitchBlade 300 with longer range and a bigger warhead. The Switchblade 300 was used extensively in Iraq and Afghanistan against 'high-value targets' from about 2012. Budget documents showed Switchblade 300s cost $52,914 a shot , but there was no information on the exact pricing of the 600, until now.,
Follow the Money
The U.S. Army's procurement budget for missiles for FY2026, released last month, gives a little more detail on LASSO and the rationale for it:
'Infantry Brigade Combat Teams (IBCTs) lack adequate proportional organic capabilities at echelon to apply immediate, point, long range, and direct fire effects to destroy tanks, light armored vehicles, hardened targets, defilade, and personnel targets, while producing minimal collateral damage in complex terrain in all environmental conditions.' LASSO will 'enable the Soldier to make multiple orbits within the IBCT typically assigned battlespace, to acquire and attack targets within and beyond current crew served and small arms fire'
In other words, doing exactly what FPVs do in Ukraine.
But how many would be acquired and for how much?
The document shows the Army is buying 294 SwitchBlade 600 LASSO rounds at a cost of $170,000 each.
In addition, the Army is also acquiring 54 ground control units; rather than the commercial controllers costing a few hundred dollars seen in the hands of Ukrainian FPV operators, these go for $69,204 each.
This really goes to show what has been observed many times before: that producing high-specification gear in tiny quantities means you pay boutique prices.
That tiny quantity will limit the number of operators trained, and they are not going to be firing a lot of live rounds in training.
The Javelin missile costs more than SwitchBlade 600, has a much shorter range, and requires the ... More target to be within sight
It is worth noting at $170k a shot only looks extravagant in the context of the hardware used by Russian and Ukraine. By military standards it is fairly normal. The same procurement budget shows the Army's latest batch of Javelin anti-tank missiles costing $221k apiece – and the reusable control unit needed to fire them is another $208k.
And if that sounds pricey the Army's new hypersonic LRHW missile will cost a whopping $36 million a time. 'Expensive' is all a matter of what you are used to.
FPVs For the Army
In another budget though, we find that the Army is also getting something more like the FPVs used in Ukraine via a very different program.
The Army's Aircraft budget for FY2026 includes money for 'FPV/PBAS' – 'PBAS' being 'Purpose Built Attritable System' which is the Army's new buzzword for expendable drones. The PBAS will carry a variety of 'lethal/non-lethal armaments and munitions.' As in Ukraine these may be fitted along with the battery immediately before launch.
One PBAS system consists of 'First Person Viewer (FPV) goggles, controller, leader display, two 10" air vehicles and four 5" air vehicles' and costs $34,826. Depending on the other items, the drones are likely around $5k each.
Making drones in the U.S. will always be more expensive because they cannot simple use low-cost Chinese components like the Ukrainians and Russians, and labor and other costs will inevitable be higher. $5k may be expensive by Ukrainian standards, but it will conform to U.S. military specifications, and the production run is small.
Considering that only 1,057 systems are being ordered, the $5k price tag may be the best that can be expected. It does at least mean that this program is delivering more than 20 times as many attack drones as LASSO for less total cost.
The PBAS requirement is being met by a variety of suppliers, likely including Neros, previously noted for supplying thousands of FPVs to Ukraine. Neros co-founder and CEO Soren Monroe-Anderson told me that in Ukraine he was told that any firm wishing to supply the market needed to be able to supply 5,000 FPVs a month or go home, and their business is based on large numbers of low-cost drones.
Neros' Archer is a low-cost, U.S.-made attack drone currently being supplied to Ukraine
This week Monroe-Anderson told Defence News that Neros is aiming to be able to produce 10,000 drones monthly by January, and that the longer-term vision a factory to produce one million drones per year with the U.S. Defense Department as its primary customer.
The Real Battle
These budget documents reveal the battle inside Army procurement between traditional legacy suppliers and high-cost established products against disruptive newcomers offering low-cost tech in vast numbers.
To an outsider, the way forward might seem obvious. But the defense business has its own way of working. In Ukraine and Russia, FPVs were so vital that many soldiers started out buying drones with their own money until the military procurement process finally started supplying them.
Another chink appeared this week with an Army call for solicitations, with the goal of acquiring thousands of drones rapidly at a cost of less than $2k a unit. They want more, faster, cheaper than LASSO.
Maybe next year will see the Army putting its money behind small drones in a big way. But an entrenched bureaucracy is a tougher opponent to shift than a dug-in tank battalion.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Oracle, Google cloud units strike deal for Oracle to sell Gemini models
Oracle, Google cloud units strike deal for Oracle to sell Gemini models

Yahoo

time18 minutes ago

  • Yahoo

Oracle, Google cloud units strike deal for Oracle to sell Gemini models

By Stephen Nellis SAN FRANCISCO (Reuters) -Oracle and Alphabet said on Thursday their cloud computing units have struck a deal to offer Google's Gemini artificial intelligence models through Oracle's cloud computing services and business applications. The deal, similar to one that Oracle struck with Elon Musk's xAI in June, will let software developers tap Google's models to generate text, video, images and audio while using Oracle's cloud. Businesses that use Oracle's various applications for corporate finances, human resources and supply chain planning will also be able to choose to use Google's models inside those apps. Those Oracle customers will be able to pay for the Google AI technologies using the same system of Oracle cloud credits they use to pay for Oracle services. The two companies did not disclose what, if any, payments will flow between them as part of the deal. For Oracle, the move advances the company's strategy of offering a menu of AI options to its customers rather than trying to push its own technology. For Google, it represents another step in its effort to expand the reach of its cloud offerings and win corporate customers away from rivals such as Microsoft. Sign in to access your portfolio

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

Yahoo

time18 minutes ago

  • Yahoo

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company'), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months. Strategic alliances forged during fiscal 2025 and 2026 have positioned us to capitalize on expansive market channels, providing access to approximately 90% of all hospitals in America and opening the door to managed care programs, which is a new vertical strategy for Biotricity. These developments mark a significant leap forward in our mission to deliver innovative, accessible, and high-quality cardiac care solutions." Q1-FY26 Financial Highlights Revenue increased 21% to $3.9 million, compared with $3.2 million in Q4 FY24 Gross margin was 80.5% for the three months ended June 30, 2025, as compared to 73.8% in the corresponding prior year quarter; this is the result of expansion in the recurring technology fee revenue base, efficiencies gained in using proprietary AI in operational automation, and improvement in monitoring and cloud cost structure. Net loss decreased to $0.75 million, or $0.03 per share, from a net loss of $6.9 million, or $0.49 per share, in Q1-FY25; this was an 80.6% improvement even after removing the effects of a $3 million one-time deemed dividend in the corresponding prior year period. Positive EBITDA of $333,337, first time in the Company's history; EBITDA increased by 118.7% compared to corresponding prior year quarter; this is the result of growth and operating efficiencies. Operating Highlights for Q1-FY26 and the Future Q1-FY26 recurring (TaaS) Technology Fees rose a robust 11.8% from the corresponding period of the prior year, to $3.4 million, which is also 7.9% increase from the immediately preceding three-month period. Company maintained its track record of strong customer retention, supported by the quality of customer and physician-friendly support services which emphasize the accuracy of our diagnostics and ease-of-use of our solution. Leveraging on its adept development of a range of state-of-the-art products to service a total addressable market of $35 billion. Working on achieving regulatory approval in internation markets, with a view to laying the foundation for distribution in those markets in the coming years, after successfully achieving approvals in Canada, Saudi Arabia and Argentina. Expansion of geographic footprint across 70% of the US, with penetration across thousands of physicians over hundreds of centers, including those acquired through relationships with strategic partners. Secured strategic alliances with three of the top GPOs representing 90% of all hospitals in the US. Full details of the Company's financial results will be filed with the SEC on Form 10-Q and available by visiting Financial Results and Business Update Conference Call Management will host a conference call on Thursday August 14, 2025 at 4:30 p.m. ET to discuss its financial results for fiscal first quarter of 2026 and provide a business update. Additional details are available under the Investor Relations section of the Company's website: Event: Biotricity First Quarter Fiscal 2026 Financial Results and Business Update CallDate: Thursday, August 14, 2025Time: 4:30pm ET (1:30pm PT) Toll Free: 1-877-269-7751 International: 1-201-389-0908 Webcast URL: Investors can begin accessing the webcast 15 minutes before the call, where an operator will register your name and organization. The call will be in listen-only mode. A replay of the call will be available approximately three hours after the live call via the Investors section of the Biotricity website at Toll Free Replay Number: 1-844-512-2921 International: 1-412-317-6671 Replay Access ID: 13755374Expiration: Thursday, August 28, 2025 at 11:59 PM ET About Biotricity Inc. Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The Company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit Non-GAAP Measures Non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies. It is management's intent to provide non-GAAP financial information to enhance the understanding of Biotricity's GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess business performance. Earnings before interest, tax, depreciation and amortization ('EBITDA') is one such measure: 3 months endedJune 30,2025 3 months endedJune 30,2024 $ $ Net loss attributable to common stockholders (754,293 ) (6,948,292 ) Add: Provision for income taxes - - Interest expense 850,254 768,673 Accretion and amortization expenses 153,572 1,144,728 Depreciation 1,488 1,488 Preferred stock dividends 82,316 3,253,772 EBITDA 333,337 (1,779,631 ) Weighted average number of common shares outstanding 26,284,734 14,169,441 Profit (Loss) per Share, Basic and Diluted 0.013 (0.126 ) Important Cautions Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Contacts Investor RelationsBiotricity Investor RelationsInvestors@ SOURCE: Biotricity Inc.

Where Will Arista Networks Stock Be in 3 Years?
Where Will Arista Networks Stock Be in 3 Years?

Yahoo

time18 minutes ago

  • Yahoo

Where Will Arista Networks Stock Be in 3 Years?

Key Points Its revenue and earnings jumped impressively last quarter thanks to the huge addressable market. Its components play a central role in AI data centers, and it has been gaining a greater share. While the stock is expensive right now, outstanding growth could help it justify the valuation. 10 stocks we like better than Arista Networks › Arista Networks (NYSE: ANET) is a key player in the cloud computing industry, as its networking components and software offerings enable fast data transmission in data centers. The company is now benefiting from the heavy investments in artificial intelligence (AI) infrastructure. This explains why Arista's latest results for the second quarter turned out to be better than Wall Street's expectations. Arista stock shot up more than 17% following the release of its quarterly results on Aug. 5. Arista didn't just beat expectations -- it also raised its full-year revenue guidance substantially. Arista's latest pop brings the stock's gains over the past three years to a whopping 360% as of this writing. However, will the company be able to sustain this impressive momentum over the next three years as well? Let's find out. Arista Networks' growth rate is likely to improve further Arista's Q2 revenue shot up 30% year over year to $2.2 billion, while its non-GAAP earnings jumped nearly 38% from the year-ago period to $0.73 per share. The company points out that the strong demand for its networking components, such as switches and routers, from AI hyperscalers and cloud computing providers was the catalyst behind its robust growth. Even better, Arista is now expecting its 2025 revenue to increase by 25%, as compared to the earlier estimate of 17%. Looking ahead, the possibility of Arista further increasing its guidance cannot be ruled out. After all, the company points out that the high-speed networking delivered by its switches and routers can reduce the operating costs of AI data centers. Arista claims that 30% to 50% of the processing time in data centers is wasted in transferring data in AI clusters powered by graphics processing units (GPUs). The company's offerings allow data center operators to improve their network utilization rates, thereby leading to lower costs. Not surprisingly, the company expects its AI-related networking revenue to exceed its $1.5 billion estimate in 2025. The company is confident of maintaining healthy growth in the AI business in the long run as well, and that's not surprising. Grand View Research is projecting a 4x jump in the data center networking market's revenue between 2025 and 2033 to almost $155 billion at the end of the forecast period. Arista itself sees its total addressable market (TAM) jumping to $70 billion by 2028 from $41 billion last year. This increase in the company's TAM over the next three years should ensure healthy growth for the company, especially considering its improving market share. Arista points out that it controlled a third of the high-speed data center switching market at the end of 2024, up by 3.5 percentage points from the previous year. Importantly, Arista has been gradually taking share away from Cisco Systems in this space over the past several years, with its market share growing from just 3.5% in 2012 to more than 30% last year. So, a combination of market share gains and the overall growth of the data center networking market could help this AI stock deliver more upside. However, investors may be concerned about one thing right now. The stock is expensive right now Though Arista Networks has been growing at a nice clip, the stock seems to have run ahead of itself if we take a closer look at its valuation. Its price-to-earnings ratio of 54 is on the expensive side, which means that it will have to continue outperforming analysts' expectations consistently to sustain its stock market rally. But the good part is that Arista's growth estimates have been hiked for the next three years following its latest quarterly report. We have already seen that Arista's potential revenue opportunity is on track to jump significantly. Additionally, its market share has been improving. So, Arista seems capable of outperforming Wall Street's estimates over the next three years. In fact, the company expects to achieve its $10 billion annual revenue target in 2026, two years ahead of its original expectation. As such, there is a strong possibility of Arista's growth turning out to be better than estimates, which should allow it to justify its premium valuation and deliver more gains to investors over the next three years. Should you invest $1,000 in Arista Networks right now? Before you buy stock in Arista Networks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Arista Networks wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,783!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,122,682!* Now, it's worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Arista Networks and Cisco Systems. The Motley Fool has a disclosure policy. Where Will Arista Networks Stock Be in 3 Years? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store